| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | |
|---|---|---|---|---|---|---|
Assets | ||||||
Current assets: | ||||||
Cash and cash equivalents | ||||||
154,187 | 180,886 | 206,265 | 226,099 | 116,499 | 103,193 | |
Accounts receivable | ||||||
3,858 | 965 | 250 | 250 | 6,157 | 523 | |
Prepaid expenses | ||||||
7,862 | 9,497 | 10,738 | 8,265 | 8,299 | 8,913 | |
Other current assets | ||||||
934 | 2,324 | 2,248 | 2,474 | 6,025 | 3,046 | |
Total current assets | ||||||
166,841 | 193,672 | 219,501 | 237,088 | 136,980 | 115,675 | |
Property, equipment, and software—net | ||||||
38,784 | 39,571 | 38,959 | 32,962 | 27,908 | 21,147 | |
Intangible assets—net | ||||||
1,417 | 1,432 | 1,446 | 1,453 | 1,460 | 1,466 | |
Right-of-use assets | ||||||
6,588 | - | - | - | - | - | |
Other assets | ||||||
572 | 558 | 392 | 417 | 453 | 312 | |
Total assets | ||||||
214,202 | 235,233 | 260,298 | 271,920 | 166,801 | 138,600 | |
Liabilities and Stockholders’ Equity | ||||||
Current liabilities: | ||||||
Accounts payable | ||||||
1,766 | 2,037 | 4,465 | 2,882 | 5,057 | 2,218 | |
Accrued compensation | ||||||
1,988 | 4,425 | 2,961 | - | - | 965 | |
Accrued clinical and research and development expenses | ||||||
2,534 | 2,400 | 3,556 | - | - | 1,569 | |
Accrued other expenses and other current liabilities | ||||||
2,433 | 1,584 | 1,977 | 5,809 | 4,416 | 887 | |
Convertible notes payable | ||||||
- | - | - | - | 52,440 | - | |
Deferred revenue | ||||||
13,307 | 16,486 | 10,767 | 7,129 | 9,471 | 8,436 | |
Lease liabilities | ||||||
1,729 | - | - | - | - | - | |
Total current liabilities | ||||||
23,757 | 26,932 | 23,726 | 15,820 | 71,384 | 14,075 | |
Deferred revenue—noncurrent | ||||||
65,935 | 65,895 | 77,887 | 79,245 | 81,722 | 82,807 | |
Deferred rent—noncurrent | ||||||
- | 4,092 | 2,897 | 2,877 | 2,865 | 1,758 | |
Lease liabilities—noncurrent | ||||||
9,476 | - | - | - | - | - | |
Total liabilities | ||||||
99,168 | 96,919 | 104,510 | 97,942 | 155,971 | 98,640 | |
Stockholders’ equity: | ||||||
Additional paid-in capital | ||||||
319,889 | 316,333 | 312,891 | 310,339 | 127,750 | 126,094 | |
Accumulated deficit | ||||||
-203,903 | -177,067 | -156,151 | -135,409 | -115,973 | -85,187 | |
Treasury stock | ||||||
952 | 952 | 952 | 952 | 952 | 952 | |
Total stockholders’ equity | ||||||
115,034 | 138,314 | 155,788 | 173,978 | 10,830 | 39,960 | |
Total liabilities and stockholders’ equity | ||||||
214,202 | 235,233 | 260,298 | 271,920 | 166,801 | 138,600 | |
Series A Convertible Preferred Stock | ||||||
Preferred stock | ||||||
- | - | - | - | 3 | 3 | |
Total stockholders’ equity | ||||||
- | - | - | - | 3 | 3 | |
Series B Convertible Preferred Stock | ||||||
Preferred stock | ||||||
- | - | - | - | 2 | 2 | |
Total stockholders’ equity | ||||||
- | - | - | - | 2 | 2 | |